
Concurrence (Ali Kokar) explains why healthcare hasn’t learned from patients despite decades of data, and how AI can enable “super intelligent care” by capturing richer, causal context across the care journey. It also covers founder strategy: being early vs “wrong,” avoiding “small poisonous ponds,” and earning trust in skeptical healthcare markets.
Ali Kokar, co-founder and CEO of Concurrence. Background claims in episode: brought in Dr. Jay Shah (ex–Stanford Health chief of physician staff) as chief medical officer; Haitham (ex–NIH lead/director) leads deployments. Sabrina Albert (Madrona partner) hosts.
patient records are visit snapshots focused on billing/compliance, not outcomes; new tech can sit in the line of care to capture net-new context; trust must be deeply earned via safety/reliability and compliance; skip RCM/point solutions to focus on care-delivery outcomes.
global customer in 7 countries running post-prescription side-effect management/health coaching; 10M+ patient conversations; ~3x medication adherence lift; study found ~60% of durable patient context came from conversations, not devices/tests/visits.
Written by AI. May contain mistakes.
Exploring the future of healthcare with continuous learning systems.
“We're going to see health systems that are continuously learning from every act of care that they're delivering.”
Discussing the importance of skepticism in healthcare innovations.
“Customers in this space should be skeptical.”
Understanding the challenges healthcare faces in leveraging patient data.
“In an era of unprecedented innovation, plenty of founders are building for capabilities that don't yet exist.”
Ali explains Concurrence's approach to capturing patient health data.
“Maybe we start by understanding what is it that you're building today that wasn't possible before and why are you sure it will be?”
Defining the concept of super intelligent care and its implications.
“Is that a different way than you're thinking about it, this idea of causal understanding?”
Ali discusses the founder's perspective on timing and product market fit.
“So what we usually do when we start working with some of these larger health systems is one, build this unified understanding of their entire ecosystem with a very patient-centric view.”
Exploring the pitfalls of focusing too narrowly in healthcare ventures.
“And I'm curious, what is the founder's job in all of this?”
Ali talks about the tough decisions founders face regarding opportunities.
“okay, can we actually deliver value today to that end patient, to that health system?”
Discussing strategies to earn trust from customers in healthcare.
“And then you're also going to emerge and then you're also going to your PCP.”
Ali explains how healthcare can better utilize data to improve outcomes.
“that then can really, really drive lots of value and impact.”
How AI is transforming the understanding and management of patient care.
“but it is already paying us quite a bit of dividends.”
An example of how Concurrence improves patient engagement and adherence.
“And these companies have already invested so much in building out their platform of choice, be that with Databricks and the cloud partners.”
Learn how a healthcare organization enhances patient adherence through conversations.
“be that kind of in the pre-visit workflows, but often in the traditional visit workflow.”
Discover how digital conversations improve provider understanding of patient needs.
“Here's why she needs to come in for a visit.”
Explore how digital twins collect durable patient knowledge for better care.
“And so like it really proved out to us that when you can put these agents safely, reliably in the line of care, you can collect net new context that then is so durable and helps inform the care of that individual.”
Learn about the strategic changes that led to rebranding and expanded mission.
“So I want to, you know, So when we first met, I guess it's been over a year now, the company was actually called Amigo.”
Understand the importance of safety evaluation in healthcare technology deployment.
“And so the way we've been thinking about the talent and the people at this company has been very much a big shift.”
Envision the future where health systems learn continuously to improve care.
“So I love that about your guys' focus and the thesis has always resonated with me.”

Get the gist, explore an idea or ask about something said.
On Founded & Funded, what are the key points of this episode?
Automatic transcript. May contain errors.
0:00Sabrina Albert: We're going to see health systems that are continuously learning from every act of care that they're delivering. And then for that patient, the dream of end state precision care is finally going to be real. The feeling of hundreds of providers who are constantly sitting there making sure that they know everything about you to give you the best care possible is a dream that will finally be true. As a founder, the thing I think about always is like being too early is essentially the same as being wrong. Customers in this space should be skeptical. Skepticism is good. There's a lot of players saying a lot of different things.
0:28Sabrina Albert: Trust has to be quite deeply earned in the space, especially in the context of when you're ever engaging with patients.
0:39Ali Khokhar: Welcome to Founded and Funded. I'm Adrona partner Sabrina Albert, and today I'm here with Ali Kokar, co-founder and CEO of Concurrence. In this episode, we dig into Concurrence's goal of helping healthcare organizations learn from every patient they treat. why that's been so difficult despite decades of medical data, and what breakthroughs Ali believes could finally make this possible. We also talk about how to build a company before all the pieces are in place, how to tell whether you're early or wrong, which opportunities to pass up, and how to earn the trust of healthcare customers who are skeptical by design.
1:12Ali Khokhar: With that, let's dive in. Thanks for being here, Ali.
1:16Sabrina Albert: Thank you. Excited to be here.
1:17Ali Khokhar: In an era of unprecedented innovation, plenty of founders are building for capabilities that don't yet exist. You're doing it in the health and medical sector where the stakes are huge and historically the buyers have been slower. So despite all the tech and data that's out there, healthcare companies are not learning from the patients they treat. I think this is a problem that would sound pretty straightforward to solve, but it's been a very persistent problem over the last many decades. Maybe we start by understanding what is it that you're building today that wasn't possible before and why are you sure it will be?
1:49Sabrina Albert: The way I think about it is at Concurrence, we're trying to build a causal understanding of human health. Historically, this has never been possible, especially because inside of a patient record or a patient summary, all it is is really summarizing what that visit was. Especially because it's very anchored around billing and compliance. It's not really anchored around driving patient outcomes. Now, for the first time, you have this new technology that is actually able to sit in the line of care delivery and capture a lot more richer understanding and context about a patient. That really rich understanding then allows you for the first time, get a good sense of what is actually driving certain outcomes.
2:28Sabrina Albert: And so because of this sort of core technical breakthrough for the first time, we're able to capture net new information, make sense of it in a way that was never possible before, and as a result sort of understand how to drive certain outcomes.
2:41Ali Khokhar: And I've heard in the market this term called medical superintelligence. Is that a different way than you're thinking about it, this idea of causal understanding? Maybe unpack that a little bit more for us.
2:52Sabrina Albert: When most people think of this term medical superintelligence, which is very loaded, right, you usually think of this monolithic system that is superhuman and better than any doctor, any provider. We don't actually necessarily think of it that way. we think of it as more of a continuously learning system that is really focused on understanding what is driving certain outcomes and then being able to actually deliver that care in a meaningful way. And in some cases, that might mean actually helping those providers deliver that superhuman care. We actually prefer the term super intelligent care versus medical super intelligent because it's more around the system that is continuously learning, continuously evolving, where you have a really rich understanding of every single patient to then actually deliver that end care.
3:33Ali Khokhar: Okay, so taking a step back, what does this actually mean for health systems and providers that you're working with and how can they actually deliver tangible care?
3:41Sabrina Albert: So what we usually do when we start working with some of these larger health systems is one, build this unified understanding of their entire ecosystem with a very patient-centric view. We call this sort of the health world model. And then on top of that, we work with them to build very bespoke, very custom patient-facing or provider-facing agentic workflows. So you can think a patient is coming into a visit. Before a visit, there's a bunch of things that need to happen. They need to make sure their appointment is booked. We do intake, triage, and so on and so forth. The visit itself is a really rich, important piece of context that we want to capture and support and give a lot of information to that provider.
4:15Sabrina Albert: And then after that visit, everything that takes place from making sure that they're actually going, if they were referred to a specialist, that they actually go have that appointment booked, they can actually show up. If they're prescribed medication, side effect management is a big piece. Medication adherence is a big piece. So a lot of our sort of focused solutions end up being across that patient journey and sitting in the line of care delivery, but very often supporting that health system across the board.
4:40Ali Khokhar: So we talked about your framing of this idea of super intelligent care. And when the conditions are finally right, I think they unlock a series of breakthroughs that can make an idea seem almost inevitable. And I'm curious, what is the founder's job in all of this? And how do you tell from being early versus being wrong? And what would you watch out for?
4:59Sabrina Albert: As a founder, the thing I think about always is like being too early is essentially the same as being wrong. And so we started thinking through what are the right sort of conditions in this space right now that allow us to have the belief that this end state is going to be inevitable and a reality and that we should start building towards it. But at the same time, then, what are we doing today tangibly to continuously sort of build towards that future? At the macro level, you can think of it as a massive industry mindset shift around adopting that new technology. That's for sure the case in healthcare.
5:30Sabrina Albert: The regulatory environment is changing. The FDA is way more open and comfortable with a lot of these AI systems being and sitting at the line of care, helping drive patient outcomes. There's obviously technology breakthroughs. These foundational models are continuously getting better and better. They still need the right system and orchestration around them, and that's where we focus a lot of our energy on. But most importantly, there's this thought around, okay, can we actually deliver value today to that end patient, to that health system? And that's very clearly yes, through a lot of the use cases, like I mentioned, across that patient journey, while also having and building the foundation towards this end state future that is almost inevitable.
6:08Sabrina Albert: And so we sort of think of it as making sure that there's short term value being delivered and the product that we're building is very intentionally built so that that super intelligent care world is inevitable for us.
6:18Ali Khokhar: And as you situate yourself for this future playing fields, we talked a little bit earlier about avoiding small poisonous ponds. What does that mean when you put into practice?
6:26Sabrina Albert: Yeah, I think a lot of founders, especially in healthcare, fall into this trap. Maybe I'll help define it a little bit. The way I think about it is, there's a lot of sort of very narrow ponds we think of them inside in the context of healthcare where folks are building companies. And so a lot of my founder friends have said, okay, let's pick one sort of very specific industry, one specific vertical, orthopedics, dental, behavioral health, whatever the case may be. let's then pick one specific workflow and just build a product and company around automating that now that is actually like standard conventional startup advice is like go super narrow and super deep on a specific problem i think the the challenge for why it does not work in healthcare is that as soon as you go into that you'll start realizing that to actually drive and patient outcomes and sort of deliver a lot of value you need to touch many different problems across that patient journey across even many different industries right because you think of it as a patient, you're not actually saying, oh, cool, I want to go and do sort of like therapy at this provider specifically.
7:28Sabrina Albert: And then you're also going to emerge and then you're also going to your PCP. And that same patient is having sort of various touch points with the healthcare industry. Companies who are then saying, I'm just going to automate this end up getting stuck because you then have all these other problems in terms of mid-retaining context, supporting that patient across various aspects of that journey, inside of that ecosystem, inside of that health organization, but then also beyond. And so we then say, okay, building in that very narrow way, we think of it as sort of this small poisonous pond almost, where you go in there with the right initial mindset around conventional startup wisdom, but then you get caught.
8:04Sabrina Albert: And so we took the approach of, if we just zoom out and look at the entire industry as a whole, what are the foundational building blocks we should be building from an infrastructure standpoint, from a safety reliability standpoint, from a understanding of patient across their entire life standpoint that then can really, really drive lots of value and impact. And so that's sort of one thing that we always think about is how do we make sure we're not sort of falling into that trap?
8:26Ali Khokhar: Okay, so tell us about a pod that you deliberately walked past. It's obviously hard sometimes in the moment to walk past these things when you think that there's a really big opportunity ahead of you. But as a founder, it's your job to think about prioritization of these things. What did it cost you and how do you think about the trade-offs?
8:41Sabrina Albert: Oh my God, a lot. We've had to make some very tough decisions around how we've defined our product and platform strategy, which opportunities we've said no to. Like an obvious example is RCM, right? Everybody in the industry, all of my final friends often just say, just go to RCM. That's where a lot of money is at. Just go focus your energy on that. The ROI is clear and so on and so forth. And that's fair and that's true. However, we wanted to really, really focus a lot of our energy on what does it actually mean to deliver care? What does it actually mean to drive those outcomes? and sort of being and sitting at the point of RevCycle management or prior auth or even ambient listening, all of these sort of point solutions make sense and can be very lucrative in the short term, but in the long term can cause a lot of challenges around how you think about then your product strategy, how you think about what you're trying to build, who you're selling to and so on and so forth.
9:30Sabrina Albert: And so it's a lot of opportunity costs that we say no to early on, but it is already paying us quite a bit of dividends.
9:37Ali Khokhar: I think one of the reasons people do focus on these you know, wedges as you were describing it is because healthcare as an industry has historically been more skeptical by design and they want to see the ROI, the product right away. But what are you learning as you're building at this infrastructure layer of why customers are saying yes to you? And I know you guys just announced a big partnership with Databricks as well. So maybe share a little bit about how you make it easy for the customers in a historically skeptical world to say yes.
10:05Sabrina Albert: Yeah, I always say customers in this space should be skeptical. Skepticism is good. There's a lot of players in this space saying a lot of different things. And so we actually love working with folks who are quite skeptical. The way we think about it is like trust has to be quite deeply earned in the space, earned especially in the context of when you're ever engaging with patients in any way, shape, or form. And so we think of that whether it's in the context of safety or reliability or how we train all of our systems, how all of our customers are part of that equation so they get to really shape it and really understand how these systems are going to behave.
10:39Sabrina Albert: I think in the context of what we're building, having an understanding of sort of a true longitudinal patient record is really important. That means having access to data that is super sensitive. That means talking and spending a lot of time with compliance and legal teams. And that's all great. We should be doing that. And so in an effort to try to make some of those things really easy, we'll come to you wherever your entire ecosystem is built. Whether you're on a Databricks, whether you're on an Azure or Snowflake, whatever the case may be, we'll come in and work inside of your existing government environments and really help accelerate your journey that you've taken already.
11:14Sabrina Albert: That really helped us overcome the second batch of skepticism around, do I have to completely redo my entire business from scratch in order to work with you? And the answer is no, of course not.
11:22Ali Khokhar: Yeah. And these companies have already invested so much in building out their platform of choice, be that with Databricks and the cloud partners. And they don't want to make that transition out. They don't want to pull out their data. So if you can be at that layer in which you're partnering with them, it allows for you to have an opportunity with them. As a patient, I'm familiar with my Epic system, my chart, et cetera. And healthcare as a segment has historically generated more data than a lot of industries out there, but it hasn't made care better. And I'm curious, why do you think that is?
11:54Ali Khokhar: And what does AI actually make possible for the first time?
11:56Sabrina Albert: Yeah, I think the way I think about it is it's twofold. One is we're not collecting enough understanding and information, Right. Like I mentioned, we're seeing a patient will go in and see their PCP maybe once or twice a year. And really, that's a point in time snapshot of understanding that we now have captured. And so AI for the first time allows us to sit at the line of care and actually capture way more information and the right type of information is both at the same time. Right. So like, let's go very specific. You're a patient. You came in, you got some medication and you went home. and now we don't actually know if this medication is working or not.
12:34Sabrina Albert: And if it's not working, is it just because it's the wrong medication, it's the wrong dosage, or is it because something happened in your life that you stopped taking it altogether? All of that really rich understanding is completely missing. We need that understanding to actually build this causal understanding of human health. And so for the first time now, these systems, if built safely and reliably in the way that we've been focusing a lot of our efforts on, can actually safely sit at the line of care, communicate with you, follow up with you, understand why or why not you may or may not be taking some medication in this example, and then connect the dots back inside of that existing system, an Epic or whatever the case may be, so that that provider has a holistic, full understanding of what to do next in the context of your care.
13:16Sabrina Albert: And so it's both a matter of we're not collecting enough rich context and data about that patient, nor is it the right type. Once all of a sudden you have this technology, you can do both of those. And then you're now collecting way more understanding and information than ever before. Luckily, these foundation models, actually, if you think of them as a search primitive, are phenomenal at looking at a really large amount of data and finding causal patterns and starting to think through, okay, what is actually driving certain outcomes? And so it sort of ends up being twofold in that way.
13:47Ali Khokhar: Can you walk through an example of one of your customers and how they actually leverage concurrence today and what that actually looks like and how you're actually getting a lot of that data? Because you're powering a lot of these conversations, as you talked about before, be that kind of in the pre-visit workflows, but often in the traditional visit workflow. So actually having a conversation with the system itself. And then post-visit, how do you do the right adherence, follow-ups, et cetera?
14:14Sabrina Albert: Yeah, happy to do so. I'll give you one concrete example. We have an organization that's fairly global. We're deployed in seven different countries and we're specifically in the workflow of post-prescription of a medication doing side effect management and health coaching. And so in that case, we've done 10 million plus conversations or patient encounters there. And we've found that we've actually, through our systems, been able to drive up med adherence almost 3x in scenarios where those patients are actively engaging. And when that patient then, when we do escalate, when there is some urgent situation that shouldn't be handled by our systems, that provider now has way richer understanding and context of, hey, here's actually what's been going on with Sabrina over the last few weeks.
14:56Sabrina Albert: Here's why she needs to come in for a visit. We've booked her in, but here's a really rich context of what's been going on in her life. And so that becomes really, really important. And then we went back and sort of did a study with them to understand how are we causing a lot of really good understanding of patients. We've built these digital twins, And we found that almost 60 % of the durable knowledge and information and context about each patient was learned not from their devices, their biometric markers, their blood tests, their visits, but actually just through the conversations that we were having.
15:27Sabrina Albert: And so like it really proved out to us that when you can put these agents safely, reliably in the line of care, you can collect net new context that then is so durable and helps inform the care of that individual. of that individual. And we can sort of share a lot of that information with that entire care team, whether it's their PCP, whether it's a specialist they're being referred to, whether it's the nurse or care coordinator who's calling them after the fact or whatever the case may be.
15:52Ali Khokhar: And over time, then the patient's experience gets much better because it's more bespoke to them, the different individuals, and you're able to extract a lot of that data from existing systems, but then you're also able to pair it with this model that's improving, improving over time.
16:06Sabrina Albert: Precisely, exactly.
16:06Ali Khokhar: That's awesome. So I want to, you know, So when we first met, I guess it's been over a year now, the company was actually called Amigo. And you guys recently expanded in a lot of ways. And the company is now called Concurrence. I'm curious, what was the thesis behind doing that? The name is obviously the visible part, but what else has changed?
16:26Sabrina Albert: Yeah, the name was actually the very last thing to change. Over the last year, we've really been reorienting the company around our expanded mission. That means the type of talent and people that we hired. So we brought over Dr. Jay Shah, who was the chief of physician staff at Stanford Health before to be our chief medical officer. We brought over Haitham, who was previously a lead and director at the NIH to come in and lead a lot of our deployment function. And so the way we've been thinking about the talent and the people at this company has been very much a big shift. And then also, I would say the types of customers that we work with and serve.
16:58Sabrina Albert: So we've had some really, really amazing conversations and paths ongoing with some large governments abroad, large health systems, one of the largest pharma companies in the world, who all want to sort of go and influence and impact how care is delivered. And so that's sort of also been another really exciting piece that we'll share more about soon. But the name is the very last part. Now, what doesn't change is really a lot of our focus and emphasis that has been since we first met around safety evaluation. Like what are the rigorous testing we do before any of these systems are allowed to go out and be deployed into the world?
17:31Sabrina Albert: And going back to sort of areas that we don't necessarily focus on, i.e. just helping monetization, but rather focused very heavily on patient facing care delivery.
17:40Ali Khokhar: Yeah, I think safety, patient trust in this vertical, this industry is one of the most important things and cannot be undermined in any way. So I love that about your guys' focus and the thesis has always resonated with me. And so as we think five years out, what is different for patients and providers and what do you think will have to happen for that to be true?
18:02Sabrina Albert: On the health system side more broadly, we're going to see health systems that are continuously learning from every act of care that they're delivering. They're able to get way more understanding of what's happening inside of their ecosystem and be able to really, really deliver good care at a lower cost of that care. On the provider side, specifically, we're going to be able to equip them for the first time ever, a really holistic causal understanding of what is happening inside of a patient's life, what is driving certain outcomes, and how they can deliver the best care to that end patient. And then for that patient, the dream of end state precision care is finally going to be real.
18:39Sabrina Albert: Really, the feeling of hundreds of providers who are constantly sitting there, making sure that they know everything about you to give you the best care possible is a dream that will finally be true.
18:48Ali Khokhar: I'm excited for that future state. I think with the tech and what you guys are building at Concurrence, we can actually get there, which is a big reason that Madron is excited to be an investor in you guys from day one. And as a patient, I'm hopeful for that experience as well. So thanks very much, Ali, for being here with us today. This was a lot of fun.
19:07Sabrina Albert: Of course. Thank you for having me.
Building a company before all the pieces are in place forces calls on timing, focus, and trust. Concurrence co-founder and CEO Ali Khokhar shares how he has made them while building AI for health systems.
Concurrence (formerly Amigo) captures context at the line of care so health systems can learn from every patient they treat. In this episode, Madrona partner Sabrina Albert talks with Ali about the decisions behind it.
What founders can take from this conversation:
1) How to test whether you're early or wrong.
2) When "go narrow and deep" stops working.
2) How to say no to obvious money. Friends pointed him to revenue cycle management because the ROI is clear. Ali passed and says the opportunity costs are already paying dividends.
3) How to sell to skeptical buyers.
4) How to collect net new context.
Founders building ahead of the market, in a regulated industry, or for cautious buyers will find specific decisions on timing, focus, and trust that they can test against their own company.
Transcript: https://www.madrona.com/is-your-startup-idea-too-early-or-the-wrong-thing
Chapters:
00:00 – Introduction
02:52 – Superintelligent Care vs. Medical Superintelligence
04:59 – How to Tell Whether a Startup Is Early or Wrong
06:27 – Why Go-Narrow Startup Advice Becomes a Small Poisonous Pond in Healthcare
08:26 – When a startup has to say no to revenue to accomplish long term product strategy
09:37 – Earning Trust From Skeptical Buyers
11:39 – Why Decades of Healthcare Data Have Not Made Care Better
14:20 – Example of What Concurrence Does
16:06 – Why Amigo Became Concurrence: Expanding a mission
18:02 – What Healthcare Looks Like in Five Years